REDWOOD CITY, Calif.--(BUSINESS WIRE)--Natera, formerly known as Gene Security Network, today announced that data from studies of the company’s bioinformatics Parental Support technology will be presented during the American College of Medical Genetics 2012 Annual Clinical Genetics Meeting at the Charlotte Convention Center in Charlotte, North Carolina.
Matthew Rabinowitz, Ph.D., CEO of Natera, will deliver an oral presentation, abstract 59, titled “First Trimester Non-invasive Detection of Fetal Aneuploidy 13, 18, 21, and X by Targeted Sequencing.” The session will begin at 3:45 p.m. EDT on Friday, March 30. Dr. Rabinowitz will discuss how Natera’s core technology allows for early and accurate screening of fetal aneuploidy 13, 18, 21 and X.
During the same session, Ruth Lathi, M.D., Director of the Recurrent Pregnancy Loss Program at Stanford University , will deliver an oral presentation, abstract 58, titled “Informatics-based Molecular Karyotyping of Products of Conception (POC) with Maternal Cell Contamination (MCC) Detection: Report on 1,222 Consecutive Analyses.”
In addition, Brynn Levy, Ph.D. Director of Clinical Cytogenetics at Columbia University, will present during the OBGYN Geneticists Meeting on Wednesday, March 28. His presentation, titled “Non-invasive Prenatal Diagnosis Beyond Down Syndrome: The PreNATUS Trial,” will describe the ongoing, NIH-funded clinical investigation of Natera’s non-invasive prenatal diagnostic test.
Natera is a genetic testing company that has developed a proprietary bioinformatics technology (Parental Support) to deliver accurate and comprehensive high throughput testing for reproductive indications from tiny quantities of DNA – as small as that from a single cell. Natera operates a CLIA laboratory in Redwood City, Calif., providing a host of preconception and prenatal genetic testing services. Test offerings include preimplantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an IVF cycle in order to select embryos with the highest probability of becoming healthy children; products of conception testing following miscarriage to rapidly and extensively analyze fetal chromosomes in order to understand the cause; and non-invasive prenatal testing to determine paternity or detect genetic disease by analyzing fragments of fetal DNA in a pregnant mother’s blood drawn in the first trimester. Non-invasive testing for paternity is currently available worldwide. Natera's clinical trial for non-invasive detection of chromosomal anomalies is funded by the NIH and is being conducted by the leaders in maternal-fetal medicine in the United States. For more information, visit www.natera.com.